Table 2.

Effect of dapagliflozin compared with placebo on principal components analysis defined metabolite factors

Factors	Annotations for factors	Model 1		Model 2
		Nominal P value	FDR corrected P value	Nominal P value	FDR corrected P value
Factor 1	Medium-chain acylcarnitines	0.96	0.96	0.83	0.98
Factor 2	Branched-chain and aromatic amino acids	0.25	0.83	0.31	0.95
Factor 3	Long-chain acylcarnitines	0.05	0.22	0.07	0.31
Factor 4	Long-chain dicarboxyl acylcarnitines	0.80	0.96	0.95	0.98
Factor 5	Miscellaneous amino acids	0.35	0.83	0.39	0.95
Factor 6	Ketone-related metabolites and short-chain acylcarnitines	0.02	0.11	0.01	0.08
Factor 7	Medium-chain acylcarnitines	0.01	0.09	0.01	0.08
Factor 8	Miscellaneous amino acids	0.71	0.96	0.92	0.98
Factor 9	Long-chain acylcarnitines	0.54	0.96	0.56	0.98
Factor 10	Miscellaneous amino acids	0.93	0.96	0.98	0.98
Factor 11	Branched-chain amino acids and short-chain acylcarnitines	0.86	0.96	0.96	0.98
Factor 12	Miscellaneous amino acids	0.38	0.83	0.44	0.95
Factor 13	Short-chain dicarboxyl acylcarnitines	0.82	0.96	0.82	0.98

Model 1: randomized treatment group and baseline factor level

Model 2: additionally adjusted for age, race/ethnicity, sex, eGFR, and type 2 diabetes mellitus

FDR-corrected p values <0.10 were considered statistically significant.

FDR, false discovery rate.